Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03887325
Other study ID # Maxipost P H-18052101
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2019
Est. completion date February 29, 2020

Study information

Verified date June 2020
Source Danish Headache Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is not previously investigated whether, there is a correlation between potassium channels and migraine, so it is unclear whether, this signaling pathway through potassium channels has an impact on migraine pathophysiology.

Maxipost (BMS 204352) is a vasoactive molecule that causes vasodilation via the big calcium dependent potassium (BKCa) channel signaling pathway. Maxipost decreases the blood pressure and maxipost infusion causes headache in healthy volunteers. A possible coherence between maxipost and headache/migraine in healthy volunteers and migraine patients is yet to be investigated.

The present study aims to clarify a possible coherence between maxipost and headache/migraine and it will help to shed light on the importance of potassium channels in migraine. In general, the study will contribute to a greater understanding of migraine pathogenesis and possibly lead to development of specific migraine treatment.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date February 29, 2020
Est. primary completion date February 29, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Migraine patients without aura who fulfill criteria in the international classification of headaches. This does not apply to healthy volunteers.

- 18-60 years.

- 50-90 kg.

- Women of childbearing potential must use adequate contraception.

Exclusion Criteria:

- Headache less than 48 hours before the tests start

- All primary headaches, except migraine without aura for migraine patients, according to international classification of headache

- Daily consumption of drugs of any kind other than oral contraceptives

- Pregnant or nursing women.

- Cardiovascular disease of any kind, including cerebrovascular diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Maxipost
To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Saline
To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients

Locations

Country Name City State
Denmark Danish headache center Glostrup Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence and change of migraine attack Occurrence and of migraine according to international criteria Before (-10 minutes) and after infusion (+12 hours) of maxipost compared with before and after infusion of saline
Secondary Change in cerebral hemodynamic Change on velocity of media cerebri artery. Before (-10 minutes) and after infusion (+2 hours) of maxipost compared with before and after infusion of saline
Secondary Occurrence and change of headache Occurrence of headache measured by numerical rating scale (NRS) Before (-10 minutes) and after infusion (+12 hours) of maxipost compared with before and after infusion of saline
Secondary Change of diameter of the artery Change of diameter of superficial temporal artery and radial artery. The diameter will be measured by millimeter (mm). Before (-10 minutes) and after infusion (+2 hours) of maxipost compared with before and after infusion of saline
See also
  Status Clinical Trial Phase
Recruiting NCT05503082 - Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Phase 4
Completed NCT04905654 - Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura N/A
Completed NCT04111484 - Adrenomedullin Effect on Migraine Without Patients N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT03337620 - Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine Phase 3
Completed NCT02259387 - Adolescents With Migraine: What's Stress Got To Do With It?
Completed NCT05658185 - Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient N/A
Completed NCT05001399 - Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain N/A
Completed NCT03490500 - Using the S100B Protein for Emergency Headache Management Care (S100)
Completed NCT03075020 - Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura. N/A
Recruiting NCT03472092 - Mind and Body Approaches to Pain Reduction in Youth With Migraine Phase 2
Enrolling by invitation NCT04976985 - Osteopathic Manipulative Treatment and Migraine Headaches N/A
Active, not recruiting NCT04372264 - Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache Phase 4
Recruiting NCT04623203 - The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
Completed NCT04577443 - The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties. N/A
Completed NCT03560024 - The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers N/A
Completed NCT03228355 - Headache Inducing Effect of Cromakalim in Migraine Patients N/A
Completed NCT02438553 - Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain N/A
Recruiting NCT03577548 - Influence of Main Psychological and Social Factors on Primary Headaches
Recruiting NCT04715685 - Mind Body Balance for Pediatric Migraine N/A